Mar 16, 2021

Starpharma (ASX:SPL) shares rise on breast cancer development

Starpharma (ASX:SPL) shares rise on breast cancer development

The Market Herald reported that Starpharma's second radiopharmaceutical candidate, DEP HER2-lutetium, had achieved anti-cancer activity in breast cancer, and that the drug outperformed Herceptin, a treatment for a type of breast cancer called HER2 positive. Read more here

 This contains certain forward-looking statements.